Cargando…
Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma
The objective of this study was to evaluate the feasibility of developing personalized, tumor-informed assays for patients with high-risk resectable melanoma and examine circulating tumor DNA (ctDNA) levels in relation to clinical status. Pilot prospective study of clinical stage IIB/C and resectabl...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144272/ https://www.ncbi.nlm.nih.gov/pubmed/37040662 http://dx.doi.org/10.1097/CMR.0000000000000892 |
_version_ | 1785034061553598464 |
---|---|
author | Brunsgaard, Elise K. Bowles, Tawnya L. Asare, Elliot A. Grossmann, Kenneth Boucher, Kenneth M. Grossmann, Allie Jackson, Julie A. Wada, David A. Rathore, Richa Budde, Griffin Grandemange, Andrew Hyngstrom, John R. |
author_facet | Brunsgaard, Elise K. Bowles, Tawnya L. Asare, Elliot A. Grossmann, Kenneth Boucher, Kenneth M. Grossmann, Allie Jackson, Julie A. Wada, David A. Rathore, Richa Budde, Griffin Grandemange, Andrew Hyngstrom, John R. |
author_sort | Brunsgaard, Elise K. |
collection | PubMed |
description | The objective of this study was to evaluate the feasibility of developing personalized, tumor-informed assays for patients with high-risk resectable melanoma and examine circulating tumor DNA (ctDNA) levels in relation to clinical status. Pilot prospective study of clinical stage IIB/C and resectable stage III melanoma patients. Tumor tissue was used to design bespoke somatic assays for interrogating ctDNA in patients’ plasma using a multiplex PCR (mPCR) next-generation sequencing (NGS)-based approach. Plasma samples for ctDNA analysis were collected pre-/post-surgery and during surveillance. Out of 28 patients (mean 65 years, 50% male), 13 (46%) had detectable ctDNA prior to definitive surgery and 96% (27/28) tested ctDNA-negative within 4 weeks post-surgery. Pre-surgical detection of ctDNA was significantly associated with the later-stage (P = 0.02) and clinically evident stage III disease (P = 0.007). Twenty patients continue in surveillance with serial ctDNA testing every 3–6 months. With a median follow-up of 443 days, six out of 20 (30%) patients developed detectable ctDNA levels during surveillance. All six of these patients recurred with a mean time to recurrence of 280 days. Detection of ctDNA in surveillance preceded the diagnosis of clinical recurrence in three patients, was detected concurrent with clinical recurrence in two patients and followed clinical recurrence in one patient. One additional patient developed brain metastases without detection of ctDNA during surveillance but had positive pre-surgical ctDNA. Our results demonstrate the feasibility of obtaining a personalized, tumor-informed mPCR NGS-based ctDNA assay for patients with melanoma, particularly in resectable stage III disease. |
format | Online Article Text |
id | pubmed-10144272 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-101442722023-04-29 Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma Brunsgaard, Elise K. Bowles, Tawnya L. Asare, Elliot A. Grossmann, Kenneth Boucher, Kenneth M. Grossmann, Allie Jackson, Julie A. Wada, David A. Rathore, Richa Budde, Griffin Grandemange, Andrew Hyngstrom, John R. Melanoma Res Original Articles: Translational Research The objective of this study was to evaluate the feasibility of developing personalized, tumor-informed assays for patients with high-risk resectable melanoma and examine circulating tumor DNA (ctDNA) levels in relation to clinical status. Pilot prospective study of clinical stage IIB/C and resectable stage III melanoma patients. Tumor tissue was used to design bespoke somatic assays for interrogating ctDNA in patients’ plasma using a multiplex PCR (mPCR) next-generation sequencing (NGS)-based approach. Plasma samples for ctDNA analysis were collected pre-/post-surgery and during surveillance. Out of 28 patients (mean 65 years, 50% male), 13 (46%) had detectable ctDNA prior to definitive surgery and 96% (27/28) tested ctDNA-negative within 4 weeks post-surgery. Pre-surgical detection of ctDNA was significantly associated with the later-stage (P = 0.02) and clinically evident stage III disease (P = 0.007). Twenty patients continue in surveillance with serial ctDNA testing every 3–6 months. With a median follow-up of 443 days, six out of 20 (30%) patients developed detectable ctDNA levels during surveillance. All six of these patients recurred with a mean time to recurrence of 280 days. Detection of ctDNA in surveillance preceded the diagnosis of clinical recurrence in three patients, was detected concurrent with clinical recurrence in two patients and followed clinical recurrence in one patient. One additional patient developed brain metastases without detection of ctDNA during surveillance but had positive pre-surgical ctDNA. Our results demonstrate the feasibility of obtaining a personalized, tumor-informed mPCR NGS-based ctDNA assay for patients with melanoma, particularly in resectable stage III disease. Lippincott Williams & Wilkins 2023-06 2023-04-05 /pmc/articles/PMC10144272/ /pubmed/37040662 http://dx.doi.org/10.1097/CMR.0000000000000892 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Original Articles: Translational Research Brunsgaard, Elise K. Bowles, Tawnya L. Asare, Elliot A. Grossmann, Kenneth Boucher, Kenneth M. Grossmann, Allie Jackson, Julie A. Wada, David A. Rathore, Richa Budde, Griffin Grandemange, Andrew Hyngstrom, John R. Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma |
title | Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma |
title_full | Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma |
title_fullStr | Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma |
title_full_unstemmed | Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma |
title_short | Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma |
title_sort | feasibility of personalized circulating tumor dna detection in stage ii and iii melanoma |
topic | Original Articles: Translational Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144272/ https://www.ncbi.nlm.nih.gov/pubmed/37040662 http://dx.doi.org/10.1097/CMR.0000000000000892 |
work_keys_str_mv | AT brunsgaardelisek feasibilityofpersonalizedcirculatingtumordnadetectioninstageiiandiiimelanoma AT bowlestawnyal feasibilityofpersonalizedcirculatingtumordnadetectioninstageiiandiiimelanoma AT asareelliota feasibilityofpersonalizedcirculatingtumordnadetectioninstageiiandiiimelanoma AT grossmannkenneth feasibilityofpersonalizedcirculatingtumordnadetectioninstageiiandiiimelanoma AT boucherkennethm feasibilityofpersonalizedcirculatingtumordnadetectioninstageiiandiiimelanoma AT grossmannallie feasibilityofpersonalizedcirculatingtumordnadetectioninstageiiandiiimelanoma AT jacksonjuliea feasibilityofpersonalizedcirculatingtumordnadetectioninstageiiandiiimelanoma AT wadadavida feasibilityofpersonalizedcirculatingtumordnadetectioninstageiiandiiimelanoma AT rathorericha feasibilityofpersonalizedcirculatingtumordnadetectioninstageiiandiiimelanoma AT buddegriffin feasibilityofpersonalizedcirculatingtumordnadetectioninstageiiandiiimelanoma AT grandemangeandrew feasibilityofpersonalizedcirculatingtumordnadetectioninstageiiandiiimelanoma AT hyngstromjohnr feasibilityofpersonalizedcirculatingtumordnadetectioninstageiiandiiimelanoma |